Ratings by Wedbush (Robert Driscoll)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/19/2024 | Cullinan Oncology Inc. | CGEM | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2024 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/11/2024 | Alpine Immune Sciences | ALPN | Downgrade | Neutral (Outperform) |
47.04 (64.55) |
37.22% | Details | |
| 4/8/2024 | Black Diamond Therapeutics | BDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/27/2024 | Aprea | APRE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2024 | Elevation Oncology | ELEV | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2024 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2024 | Revolution | RVMD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/15/2024 | Cullinan Oncology Inc. | CGEM | New Coverage | Outperform (N/A) |
17.91 (16.67) |
-6.92% | Details | |
| 2/15/2024 | Monte Rosa Therapeutics | GLUE | New Coverage | Outperform (N/A) |
4.26 (5.54) |
30.05% | Details | |
| 2/8/2024 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/30/2024 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/17/2024 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2024 | Revolution | RVMD | New Coverage | Outperform (N/A) |
27.99 (36.26) |
29.55% | Details | |
| 12/6/2023 | IGM Biosciences | IGMS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/5/2023 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/5/2023 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2023 | IGM Biosciences | IGMS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2023 | CytomX Therapeutics | CTMX | Upgrade | Outperform (Neutral) |
1.28 (1.68) |
31.25% | Details | |
| 11/8/2023 | Zentalis Pharmaceuticals | ZNTL | Downgrade | Neutral (Outperform) |
10.20 (12.57) |
23.24% | Details | |
| 11/7/2023 | Day One Biopharmaceuticals | DAWN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/23/2023 | Arvinas Inc. | ARVN | Upgrade | Outperform (Neutral) |
14.83 (34.00) |
129.27% | Details | |
| 8/24/2023 | Werewolf Therapeutics Inc. | HOWL | New Coverage | Outperform (N/A) |
2.46 (6.44) |
161.79% | Details | |
| 8/15/2023 | Alpine Immune Sciences | ALPN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2023 | Atreca Inc. | BCEL | Downgrade | Neutral (Outperform) |
0.56 (0.15) |
-73.21% | Details | |
| 6/30/2023 | Tyra Biosciences | TYRA | New Coverage | Outperform (N/A) |
16.69 (16.38) |
-1.86% | Details | |
| 6/27/2023 | Black Diamond Therapeutics | BDTX | Upgrade | Outperform (Neutral) |
1.84 (5.01) |
172.28% | Details | |
| 6/27/2023 | Adicet Bio Inc. | ACET | Maintain | Outperform (N/A) |
|
Details | ||
| 6/16/2023 | Surface Oncology | SURF | Downgrade | Neutral (Outperform) |
0.74 (1.07) |
44.59% | Details | |
| 6/5/2023 | Elevation Oncology | ELEV | Maintain | Outperform (N/A) |
|
Details | ||
| 5/26/2023 | Zentalis Pharmaceuticals | ZNTL | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2023 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/6/2023 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2023 | Arvinas Inc. | ARVN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/9/2023 | Day One Biopharmaceuticals | DAWN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2023 | Geron Corporation | GERN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2022 | Imago Biosciences Inc | IMGO | Downgrade | Neutral (Outperform) |
17.40 (36.01) |
106.95% | Details | |
| 11/15/2022 | Atreca Inc. | BCEL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2022 | Tango Therapeutics Inc. | TNGX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2022 | Elevation Oncology | ELEV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Surface Oncology | SURF | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2022 | Imago Biosciences Inc | IMGO | New Coverage | Outperform (N/A) |
16.54 (36.01) |
117.71% | Details | |
| 10/28/2022 | Geron Corporation | GERN | New Coverage | Outperform (N/A) |
2.39 (3.50) |
46.44% | Details | |
| 8/4/2022 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/8/2022 | Aprea | APRE | New Coverage | Outperform (N/A) |
0.83 (5.37) |
546.99% | Details | |
| 7/7/2022 | CytomX Therapeutics | CTMX | Downgrade | Neutral (Outperform) |
1.97 (1.68) |
-14.72% | Details | |
| 6/13/2022 | Day One Biopharmaceuticals | DAWN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/16/2022 | Harpoon Therapeutics | HARP | Upgrade | Outperform (Neutral) |
2.00 (23.01) |
1050.5% | Details | |
| 5/9/2022 | Arvinas Inc. | ARVN | Downgrade | Neutral (Outperform) |
45.68 (34.00) |
-25.57% | Details | |
| 5/6/2022 | Elevation Oncology | ELEV | Maintain | Outperform (N/A) |
|
Details | ||
| 3/29/2022 | Black Diamond Therapeutics | BDTX | Downgrade | Neutral (Outperform) |
2.76 (5.01) |
81.52% | Details | |
| 3/17/2022 | Cyteir Therapeutics | CYT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2022 | Entasis Therapeutics | ETTX | Downgrade | Neutral (Outperform) |
1.69 (2.19) |
29.59% | Details | |
| 3/4/2022 | Elevation Oncology | ELEV | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2022 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/21/2021 | CytomX Therapeutics | CTMX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/15/2021 | Compass Therapeutics | CMPX | New Coverage | Outperform (N/A) |
3.28 (1.52) |
-53.66% | Details | |
| 12/13/2021 | Foghorn Therapeutics | FHTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2021 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2021 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2021 | IGM Biosciences | IGMS | Upgrade | Outperform (Neutral) |
52.96 (7.70) |
-85.46% | Details | |
| 10/19/2021 | Entasis Therapeutics | ETTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/7/2021 | Tango Therapeutics Inc. | TNGX | New Coverage | Outperform (N/A) |
12.93 (7.77) |
-39.91% | Details | |
| 8/17/2021 | Black Diamond Therapeutics | BDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2021 | Surface Oncology | SURF | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2021 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/22/2021 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/20/2021 | Elevation Oncology | ELEV | New Coverage | Outperform (N/A) |
12.10 (4.32) |
-64.3% | Details | |
| 7/13/2021 | Cyteir Therapeutics | CYT | New Coverage | Outperform (N/A) |
19.65 (3.02) |
-84.63% | Details | |
| 6/21/2021 | Day One Biopharmaceuticals | DAWN | New Coverage | Outperform (N/A) |
21.00 (16.64) |
-20.76% | Details | |
| 6/7/2021 | Harpoon Therapeutics | HARP | Downgrade | Neutral (Outperform) |
15.86 (23.01) |
45.08% | Details | |
| 5/6/2021 | Entasis Therapeutics | ETTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2021 | Idera Pharmaceuticals | IDRA | Downgrade | Neutral (Outperform) |
5.21 (0.43) |
-91.75% | Details | |
| 3/11/2021 | Harpoon Therapeutics | HARP | Maintain | Outperform (N/A) |
|
Details | ||
| 3/8/2021 | Arbutus Biopharma | ABUS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/4/2021 | Five Prime Therapeutics | FPRX | Downgrade | Neutral (Outperform) |
21.26 (38.00) |
78.74% | Details | |
| 2/25/2021 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2021 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/21/2021 | Ideaya Biosciences | IDYA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/20/2021 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Outperform (N/A) |
49.13 (12.57) |
-74.41% | Details | |
| 12/22/2020 | IGM Biosciences | IGMS | Downgrade | Neutral (Outperform) |
82.94 (7.70) |
-90.72% | Details | |
| 12/17/2020 | Surface Oncology | SURF | Maintain | Outperform (N/A) |
|
Details | ||
| 12/14/2020 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2020 | Foghorn Therapeutics | FHTX | New Coverage | Outperform (N/A) |
16.05 (5.16) |
-67.85% | Details | |
| 11/9/2020 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/16/2020 | Aceto Corp. | ACET | New Coverage | Outperform (N/A) |
13.51 (2.10) |
-84.46% | Details | |
| 10/14/2020 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 10/7/2020 | Ideaya Biosciences | IDYA | New Coverage | Outperform (N/A) |
12.89 (39.02) |
202.72% | Details | |
| 8/28/2020 | Surface Oncology | SURF | New Coverage | Outperform (N/A) |
5.46 (1.07) |
-80.4% | Details | |
| 8/17/2020 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2020 | Arbutus Biopharma | ABUS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2020 | Harpoon Therapeutics | HARP | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2020 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/22/2020 | Five Prime Therapeutics | FPRX | Upgrade | Outperform (Neutral) |
4.40 (21.26) |
383.18% | Details | |
| 6/19/2020 | Alpine Immune Sciences | ALPN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2020 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | Harpoon Therapeutics | HARP | Maintain | Outperform (N/A) |
|
Details | ||
| 5/27/2020 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2020 | Arbutus Biopharma | ABUS | Upgrade | Outperform (Neutral) |
1.87 (2.75) |
47.06% | Details | |
| 5/8/2020 | CytomX Therapeutics | CTMX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2020 | Arcus Biosciences | RCUS | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2020 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2020 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2020 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/22/2020 | IGM Biosciences | IGMS | New Coverage | Outperform (N/A) |
58.54 (7.70) |
-86.85% | Details | |
| 4/22/2020 | Atreca Inc. | BCEL | New Coverage | Outperform (N/A) |
15.00 (0.15) |
-99% | Details | |
| 3/24/2020 | CytomX Therapeutics | CTMX | Upgrade | Outperform (Neutral) |
4.93 (1.68) |
-65.92% | Details | |
| 3/19/2020 | Nabriva Therapeutics AG | NBRV | Downgrade | Neutral (Outperform) |
0.50 (1.42) |
184% | Details | |
| 3/16/2020 | Idera Pharmaceuticals | IDRA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2020 | Corvus Pharmaceuticals | CRVS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2020 | Entasis Therapeutics | ETTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2020 | Cidara Therapeutics | CDTX | Maintain | (N/A) |
|
Details | ||
| 3/6/2020 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2020 | Five Prime Therapeutics | FPRX | Downgrade | Neutral (Outperform) |
4.53 (38.00) |
738.85% | Details | |
| 12/19/2019 | Paratek Pharmaceuticals | PRTK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2019 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2019 | CytomX Therapeutics | CTMX | Downgrade | Neutral (Outperform) |
5.95 (4.93) |
-17.14% | Details | |
| 10/4/2019 | Arbutus Biopharma | ABUS | Maintain | Neutral (N/A) |
|
Details | ||
| 9/25/2019 | Arvinas Inc. | ARVN | New Coverage | Outperform (N/A) |
24.41 (34.00) |
39.29% | Details | |
| 9/4/2019 | Cidara Therapeutics | CDTX | Upgrade | Outperform (Neutral) |
1.68 (0.51) |
-69.64% | Details | |
| 8/20/2019 | Nabriva Therapeutics AG | NBRV | Maintain | Outperform (N/A) |
|
Details | ||
| 6/17/2019 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/17/2019 | Cidara Therapeutics | CDTX | Downgrade | Neutral (Outperform) |
2.05 (1.68) |
-18.05% | Details | |
| 5/9/2019 | Paratek Pharmaceuticals | PRTK | Maintain | Outperform (N/A) |
|
Details | ||
| 4/25/2019 | Replimune | REPL | New Coverage | Outperform (N/A) |
0.00 (6.42) |
0% | Details | |
| 3/7/2019 | Idera Pharmaceuticals | IDRA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2019 | Paratek Pharmaceuticals | PRTK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2019 | Harpoon Therapeutics | HARP | New Coverage | Outperform (N/A) |
16.20 (23.01) |
42.04% | Details | |
| 3/1/2019 | Cidara Therapeutics | CDTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2019 | CytomX Therapeutics | CTMX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/17/2019 | Five Prime Therapeutics | FPRX | Upgrade | Outperform (Neutral) |
10.24 (4.53) |
-55.76% | Details | |
| 11/12/2018 | Achaogen | AKAO | Downgrade | Neutral (Outperform) |
2.65 (0.11) |
-95.85% | Details | |
| 10/22/2018 | Entasis Therapeutics | ETTX | New Coverage | Outperform (N/A) |
7.44 (2.19) |
-70.56% | Details | |
| 10/15/2018 | Arbutus Biopharma | ABUS | Upgrade | Neutral (Underperform) |
4.11 (2.75) |
-33.09% | Details | |
| 10/9/2018 | Arbutus Biopharma | ABUS | Downgrade | Underperform (Neutral) |
9.09 (4.11) |
-54.79% | Details | |
| 10/9/2018 | Arcus Biosciences | RCUS | New Coverage | Outperform (N/A) |
13.84 (15.50) |
11.99% | Details | |
| 8/13/2018 | Arbutus Biopharma | ABUS | Maintain | Neutral (N/A) |
|
Details |
